Press Release

Bone Health Technologies Granted Fifth U.S. Patent for Low Bone Density Treatment Osteoboost, Adds Two Key Executives

Bone Health Technologies (BHT) today announced the company has been awarded a fifth patent for Osteoboost—the first and only FDA-cleared prescription medical device to treat osteopenia…

Bone Health Technologies Secures $5 Million in Funding to Transform Osteopenia Care

Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a new $5 million funding round from leading investment firms…

Bone Health Technologies Announces FDA Clearance of Osteoboost, the First Prescription Medical Device to Treat Low Bone Density

Bone Health Technologies today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for OsteoboostTM, the first non-pharmacological device-based prescription treatment for postmenopausal women diagnosed with osteopenia…

Bone Health Technologies Awarded New Patent for Wearable Treatment for Osteopenia and Osteoporosis in Post-Menopausal Women 

Bone Health Technologies (BHT) has been granted its fourth patent to further its commercialization of the Osteoboost device.

Bone Health Technologies to Present Clinical Data at ASBMR 2023 from Pivotal Trial of Wearable Treatment for Osteopenia in Post-Menopausal Women

Osteoboost Reduced the Loss of Vertebral Bone Strength by 83% in One Year for Per Protocol Participants Vancouver, BC, Canada (October 13, 2023)– Bone Health Technologies (BHT), a leading innovator in health technologies to improve bone health, is presenting top-line results from its pivotal trial for the Osteoboost at ASBMR…
Read more